Effect of Shenqi Jiangtang granules combined with mecobalamin on blood glucose and pregnancy outcomes in patients with gestational diabetes

doi:10.3760/cma.j.issn.1007-1245.2024.17.009

Abstract

Abstract:

Objective　To investigate the effect of Shenqi Jiangtang granules combined with mecobalamin on blood glucose control and pregnancy outcomes in patients with gestational diabetes. Methods　From June 2020 to June 2023, 150 patients with gestational diabetes who were treated in Xianyang Hospital, Yan'an University were selected, and were divided into a traditional Chinese medicine group, a western medicine group, and a combined treatment group, with 50 cases in each group. The traditional Chinese medicine group were (29.33±3.65) years old and (29.75±3.22) weeks pregnant, and took conventional treatment and Shenqi Jiangtang granules 1 g/time, 3 times/d. The western medicine group were (29.16±3.06) years old and (30.51±3.41) weeks pregnant, and took conventional treatment and mecobalamin 0.5 mg/time, 3 times/d. The combined treatment group were (30.21±3.16) years old and (30.81±3.36) weeks pregnant, and took conventional treatment, Shenqi Jiangtang granules1 g/time, 3 times/d, and mecobalamin 0.5 mg/time, 3 times/d. All the 3 groups were treated 1 month. The clinical treatment effects, blood glucose qualified rates, blood glucose and lipid indicators, and pregnancy outcomes of the three groups were compared. F, t, and χ² tests were applied. Results　The therapeutic efficacy of the traditional Chinese medicine group was 70.00% (35/50), that of the western medicine group 74.00% (37/50), and that of the combined treatment group 94.00% (47/50), with a statistical difference between the 3 groups (χ²=7.523, P<0.05). After 1 month's treatment, the levels of glycosylated hemoglobin (HbA1c), 2 hours postprandial plasma glucose (2hBG), fasting blood glucose (FBG), cystatin C (Cys-C), and homocysteine (Hcy) in the combined treatment group were lower than those in the traditional Chinese medicine group and the western medicine group [(5.02±0.63)% vs. (6.33±0.79)% vs. (6.21±0.96)%, (4.02±0.53) mmol/L vs. (5.96±0.75) mmol/L vs. (5.83±0.82) mmol/L, (5.69±0.62) mmol/L vs. (7.36±0.95) mmol/L vs. (6.91±0.77) mmol/L, (8.33±0.95) μmol/L vs. (11.02±1.20) μmol/L vs. (10.86±1.25) μmol/L, and (1.01±0.11) mg/L vs. (1.31±0.16) mg/L vs. (1.28±0.15) mg/L], with statistical differences between the 3 groups (all P<0.05). The incidence of adverse pregnancy outcomes in the combined treatment group was lower than that in the Chinese medicine group and the western medicine group [8.00% (4/50) vs. 30.00% (15/50) vs. 29.00% (14/50)], with a statistical difference between the 3 groups (P<0.05). The blood glucose qualified rate and spontaneous delivery rate of the combined treatment group were obviously higher than those of the traditional Chinese medicine group and the western medicine group [94.00% (47/50) vs. 70.00% (35/50) vs. 74.00% (37/50) and 70.00% (35/50) vs. 40.00% (20/50) vs. 44.00% (22/50)], with statistical differences between the 3 groups (both P<0.05); Conclusion　Shenqi Jiangtang granules combined with mecobalamin for patients with gestational diabetes can reduce their blood glucose levels, and can improve their adverse pregnancy outcomes.

Key words:

Gestational diabetes, Shenqi Jiangtang granules, Mecobalamin, Blood glucose control, Pregnancy outcomes

摘要：

目的　探讨参芪降糖颗粒联合甲钴胺治疗对妊娠糖尿病患者血糖控制、妊娠结局的影响。方法　选取2020年6月至2023年6月在延安大学咸阳医院进行治疗的妊娠糖尿病患者150例，采用随机数字表法分为中药组、西药组和联合治疗组，各50例。中药组年龄（29.33±3.65）岁，孕周（29.75±3.22）周，在常规治疗基础上给予参芪降糖颗粒（1 g/次，3次/d）治疗；西药组年龄（29.16±3.06）岁，孕周（30.51±3.41）周，在常规治疗基础上给予甲钴胺（0.5 mg/次，3次/d）治疗；联合治疗组年龄（30.21±3.16）岁，孕周（30.81±3.36）周，在常规治疗基础上给予参芪降糖颗粒（1 g/次，3次/d）和甲钴胺（0.5 mg/次，3次/d）治疗，3组均给药治疗1个月。比较3组患者的临床疗效、血糖达标率、血糖与血脂相关指标水平及妊娠结局。统计学方法采用F检验、t检验、χ²检验。结果　中药组的总有效率为70.00%（35/50），西药组的总有效率为74.00%（37/50），联合治疗组的总有效率为94.00%（47/50），3组比较差异有统计学意义（χ²=7.523，P<0.05）。治疗1个月后，联合治疗组的糖化血红蛋白（HbA1c）、餐后2 h血糖（2hBG）、空腹血糖（FBG）、胱抑素C（Cys-C）、同型半胱氨酸（Hcy）水平均低于中药组和西药组［（5.02±0.63）%比（6.33±0.79）%比（6.21±0.96）%、（4.02±0.53）mmol/L比（5.96±0.75）mmol/L比（5.83±0.82）mmol/L、（5.69±0.62）mmol/L比（7.36±0.95）mmol/L比（6.91±0.77）mmol/L、（8.33±0.95）μmol/L比（11.02±1.20）μmol/L比（10.86±1.25）μmol/L、（1.01±0.11）mg/L比（1.31±0.16）mg/L比（1.28±0.15）mg/L］，3组比较差异均有统计学意义（均P<0.05）。联合治疗组的妊娠不良结局发生率均低于中药组和西药组［8.00%（4/50）比30.00%（15/50）比29.00%（14/50）］。联合治疗组的血糖达标率、顺产率高于中药组及西药组［94.00%（47/50）比70.00%（35/50）比74.00%（37/50）、70.00%（35/50）比40.00%（20/50）比44.00%（22/50）］，3组比较差异均有统计学意义（均P<0.05）。结论　参芪降糖颗粒联合甲钴胺治疗可降低妊娠糖尿病患者的血糖水平，改善不良妊娠结局。

关键词:

妊娠糖尿病, 参芪降糖颗粒, 甲钴胺, 血糖控制, 妊娠结局

Zhang Zan, Kang Hui, Lei Lijian.

Effect of Shenqi Jiangtang granules combined with mecobalamin on blood glucose and pregnancy outcomes in patients with gestational diabetes [J]. International Medicine and Health Guidance News, 2024, 30(17): 2863-2867.

张赞康辉雷立健.

参芪降糖颗粒联合甲钴胺对妊娠糖尿病患者血糖及妊娠结局的影响 [J]. 国际医药卫生导报, 2024, 30(17): 2863-2867.

References

[1] Plows JF, Stanley JL, Baker PN, et al. The pathophysiology of gestational diabetes mellitus[J]. Int J Mol Sci, 2018,19(11):3342. DOI: 10.3390/ijms19113342.
[2] Metzger BE, Buchanan TA. Cowie CC,et al. Diabetes in America. 3rd edition Bethesda [M]. National Institutes of Health, 2018: 1-17.
[3] Lende M, Rijhsinghani A. Gestational diabetes: overview with emphasis on medical management[J]. Int J Environ Res Public Health, 2020,17(24):9573. DOI: 10.3390/ijerph17249573.
[4] Wexler DJ, Powe CE, Barbour LA, et al. Research gaps in gestational diabetes mellitus: executive summary of a national institute of diabetes and digestive and kidney diseases workshop[J]. Obstet Gynecol, 2018,132(2):496-505. DOI: 10.1097/AOG.0000000000002726.
[5] Moon JH, Jang HC. Gestational diabetes mellitus: diagnostic approaches and maternal-offspring complications[J]. Diabetes Metab J, 2022,46(1):3-14. DOI: 10.4093/dmj.2021.0335.
[6] Rowan JA, Rush EC, Plank LD, et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7-9 years of age[J]. BMJ Open Diabetes Res Care, 2018,6(1):e000456. DOI: 10.1136/bmjdrc-2017-000456.
[7] Hanem LGE, Stridsklev S, Júlíusson PB, et al. Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: Follow-Up of Two RCTs[J]. J Clin Endocrinol Metab, 2018,103(4):1612-1621. DOI: 10.1210/jc.2017-02419.
[8] Zhang Y, Jin D, Duan Y, et al. Efficacy of mudan granule (combined with methylcobalamin) on type 2 diabetic peripheral neuropathy: study protocol for a double-blind, randomized, placebo-controlled, parallel-arm, multi-center trial[J]. Front Pharmacol, 2021,12:676503. DOI: 10.3389/fphar.2021.676503.
[9] 陈海天,张少凤,王子莲.美国糖尿病学会2019年"妊娠期糖尿病诊治指南"介绍(二)[J].中华围产医学杂志,2019,22(4):225-226.DOI:10.3760/cma.j.issn.1007-9408. 2019.04.004.
[10] 唐国一,杨红梅,杨恺欣,等.GDM患者妊娠中期血糖异常项数及妊娠晚期血糖指标与妊娠结局的关系[J].广州医药,2024,55(3):316-323.DOI:10.3969/j.issn.1000-8535.2024.03.017.
[11] Powe CE, Huston Presley LP, Locascio JJ, et al. Augmented insulin secretory response in early pregnancy[J]. Diabetologia, 2019,62(8):1445-1452. DOI: 10.1007/s00125-019-4881-6.
[12] Malaza N, Masete M, Adam S, et al. A systematic review to compare adverse pregnancy outcomes in women with pregestational diabetes and gestational diabetes[J]. Int J Environ Res Public Health. 2022 Aug 31;19(17):10846. DOI: 10.3390/ijerph191710846.
[13] McIntyre HD, Oats JJN, Kihara AB, et al. Update on diagnosis of hyperglycemia in pregnancy and gestational diabetes mellitus from FIGO's Pregnancy & Non-Communicable Diseases Committee[J]. Int J Gynaecol Obstet, 2021,154(2):189-194. DOI: 10.1002/ijgo.13764.
[14] Scholtens DM, Kuang A, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcome follow-up study (HAPO FUS): maternal glycemia and childhood glucose metabolism[J]. Diabetes Care,2019,42(3):381-392. DOI: 10.2337/dc18-2021.
[15] Gao C, Sun X, Lu L, et al. Prevalence of gestational diabetes mellitus in mainland China: a systematic review and meta-analysis[J]. J Diabetes Investig, 2019,10(1):154-162. DOI: 10.1111/jdi.12854.
[16] Alejandro EU, Mamerto TP, Chung G, et al. Gestational Diabetes Mellitus: A Harbinger of the Vicious Cycle of Diabetes[J]. Int J Mol Sci, 2020,21(14):5003. DOI: 10.3390/ijms21145003.
[17] Rasmussen L, Poulsen CW, Kampmann U, et al. Diet and healthy lifestyle in the management of gestational diabetes mellitus[J]. Nutrients,2020,12(10):3050. DOI: 10.3390/nu12103050.
[18] Kamińska K, Stenclik D, Błażejewska W, et al. Probiotics in the prevention and treatment of gestational diabetes mellitus (GDM): a review[J]. Nutrients, 2022,14(20):4303. DOI: 10.3390/nu14204303.
[19] 徐佩雯,华文进. 中医治疗妊娠期糖尿病的研究进展[J/CD]. 世界最新医学信息文摘(连续型电子期刊),2020,20(97):126-127. DOI:10.3969/j.issn.1671-3141.2020.97.046.
[20] 徐彩凤. 中医药治疗糖尿病的研究进展[J]. 继续医学教育,2022,36(9):161-164. DOI:10.3969/j.issn.1004-6763. 2022.09.041.
[21] 蔡利平,魏丹丹,汪兰芳. 参芪降糖颗粒对GDM患者糖代谢指标及分娩结局的影响[J]. 现代诊断与治疗,2023,34(7):957-959.
[22] 刘红玲. 甲钴胺联合门冬胰岛素30注射液治疗妊娠期糖尿病患者的疗效评价[J]. 黑龙江医药科学,2023,46(2):159-160. DOI:10.3969/j.issn.1008-0104.2023.02.067.
[23] Khalaf KM, Khudhair MS, Ashor AW. Vitamin B12 status and peripheral neuropathy in patients with type 2 diabetes mellitus[J]. J Pak Med Assoc, 2019,69 Suppl 3 (8):S40-S44.
[24] Didangelos T, Karlafti E, Kotzakioulafi E, et al. Efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin b12, and carnitine for 12 months in patients with diabetic neuropathy[J]. Nutrients, 2020,12(11):3254. DOI: 10.3390/nu12113254.
[25] Tiwari A, Kumar Singh R, Satone PD, et al. Metformin-induced vitamin b12 deficiency in patients with type-2 diabetes mellitus[J]. Cureus, 2023,15(10):e47771. DOI: 10.7759/cureus.47771.
[26] Lascar EM, Warner NM, Doherty MJ. Pregnancy outcomes in women with epilepsy and MTHFR mutations supplemented with methylated folate and methylcobalamin (methylated B12)[J]. Epilepsy Behav Rep, 2020,15:100419. DOI: 10.1016/j.ebr.2020.100419.